ADRB2 and neoplasm: The role of β2-AR in an effective DC-based cancer vaccination was evaluated in the murine E.G7-ovalbumin(OVA) model and turns out that blocking β2-AR together with the activation of TLR2 at the position of DC inoculation could either promote tolerogenesis or enhance anti-tumor effects (171).